Initial Statement of Beneficial Ownership (3)
August 17 2020 - 2:31PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
MULYE NIRMAL |
2. Date of Event Requiring Statement (MM/DD/YYYY)
5/22/2020
|
3. Issuer Name and Ticker or Trading Symbol
Gene Biotherapeutics, Inc. [CRXM]
|
(Last)
(First)
(Middle)
1902 RISE CONDOMINIUM, 88 SW 7TH STREET |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
MIAMI, FL 33131
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Series A Convertible Preferred Stock | (1) | (1) | Common Stock, par value $.0001 per share | 69911504 (1) | $0.0113 (1) | I | By Nostrum Pharmaceuticals, LLC |
Series B Convertible Preferred Stock | (2) | (2) | Common Stock, par value $.0001 per share | 150442478 (2) | $0.0113 (2) | I | By Nostrum Pharmaceuticals, LLC |
Explanation of Responses: |
(1) | The Reporting Person owns 220 shares of Series A Convertible Preferred Stock and has agreed to purchase up to an additional 570 shares of Series A Convertible Preferred Stock pursuant to a securities purchase agreement entered into on May 22, 2020 with Sabby Healthcare Master Fund Ltd. Each share of Series A Convertible Preferred Stock has a stated value of $1,000, which is convertible into shares of Common Stock at any time at a conversion price of $0.0113, subject to anti-dilution protection. Conversion of the Series A Convertible Preferred Stock is subject to a beneficial ownership limitation contained in the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, which prohibits a holder from converting the Series A Convertible Preferred Stock into Common Stock at any time that the holder beneficially owns more than 9.99% of the issuer's outstanding Common Stock. |
(2) | The Reporting Person owns 1,700,000 shares of Series B Convertible Preferred Stock. Each share of Series B Convertible Preferred Stock has a stated value of $1.00 per share, which is convertible into Common Stock at any time at a conversion price of $0.0113, subject to anti-dilution protection. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
MULYE NIRMAL 1902 RISE CONDOMINIUM, 88 SW 7TH STREET MIAMI, FL 33131 |
| X |
|
|
Signatures
|
/s/ Nirmal Mulye, Ph.D. | | 8/17/2020 |
**Signature of Reporting Person | Date |
Taxus Cardium Pharmaceut... (CE) (USOTC:CRXM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Taxus Cardium Pharmaceut... (CE) (USOTC:CRXM)
Historical Stock Chart
From Sep 2023 to Sep 2024